CNS Pharmaceuticals, Inc.
CNSP
$6.12
-$0.42-6.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.42M | 5.59M | 5.61M | 5.02M | 4.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.58M | 15.69M | 14.90M | 17.08M | 15.99M |
| Operating Income | -15.58M | -15.69M | -14.90M | -17.08M | -15.99M |
| Income Before Tax | -15.46M | -15.61M | -14.86M | -17.06M | -15.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.46 | -15.61 | -14.86 | -17.06 | -15.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.46M | -15.61M | -14.86M | -17.06M | -15.97M |
| EBIT | -15.58M | -15.69M | -14.90M | -17.08M | -15.99M |
| EBITDA | -15.57M | -15.69M | -14.90M | -17.08M | -15.98M |
| EPS Basic | -212.48 | -206.06 | -187.13 | -151.64 | -- |
| Normalized Basic EPS | -132.80 | -128.79 | -116.96 | -94.78 | -- |
| EPS Diluted | -212.57 | -206.15 | -187.19 | -151.64 | -- |
| Normalized Diluted EPS | -132.80 | -128.79 | -116.96 | -94.78 | -- |
| Average Basic Shares Outstanding | 723.80K | 353.70K | 126.50K | 37.00K | -- |
| Average Diluted Shares Outstanding | 723.80K | 353.70K | 126.50K | 37.00K | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |